Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:APTXNASDAQ:CBAYNASDAQ:EVLONASDAQ:MRKR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$3.94$3.63$1.42▼$11.97$234.08M1.51584,061 shs462,580 shsAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsCBAYCymaBay Therapeutics$32.48$32.40$7.26▼$32.50$3.73B0.324.11 million shs73 shsEVLOEvelo Biosciences$0.05$0.05$0.03▼$13.93$868K2.0340,811 shs488 shsMRKRMarker Therapeutics$4.37-0.9%$4.27$0.76▼$9.68$38.86M1.520,419 shs3,381 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-1.01%+34.93%+29.61%-56.56%APTXAptinyx0.00%0.00%0.00%0.00%-22.33%CBAYCymaBay Therapeutics0.00%0.00%0.00%+41.03%+220.00%EVLOEvelo Biosciences+3.39%-8.60%-8.60%-29.69%-97.72%MRKRMarker Therapeutics-0.80%+6.46%+0.81%-0.57%+436.83%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.4394 of 5 stars3.52.00.00.01.12.50.0APTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ACBAYCymaBay Therapeutics1.011 of 5 stars2.00.00.04.70.02.50.6EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33136.89% UpsideAPTXAptinyxN/AN/AN/AN/ACBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideEVLOEvelo Biosciences2.00HoldN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest MRKR, ALDX, APTX, CBAY, and EVLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/13/2024CBAYCymaBay TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$32.502/13/2024CBAYCymaBay TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$29.00 ➝ $32.50(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ACBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AMRKRMarker Therapeutics$3.31M11.74N/AN/A$1.58 per share2.76Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)APTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ACBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)Latest MRKR, ALDX, APTX, CBAY, and EVLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64APTXAptinyxN/AN/AN/ACBAYCymaBay TherapeuticsN/A10.9610.96EVLOEvelo BiosciencesN/A0.480.48MRKRMarker TherapeuticsN/A5.575.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%APTXAptinyxN/ACBAYCymaBay Therapeutics95.03%EVLOEvelo Biosciences0.31%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%APTXAptinyx10.97%CBAYCymaBay Therapeutics7.00%EVLOEvelo Biosciences1.02%MRKRMarker Therapeutics24.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.41 million54.60 millionOptionableAPTXAptinyx12N/AN/ANot OptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataMRKRMarker Therapeutics88.90 million6.76 millionNot OptionableMRKR, ALDX, APTX, CBAY, and EVLO HeadlinesSourceHeadlineHistorical signs getting TLC for National Historic Marker Daythedailynewsonline.com - April 26 at 2:57 AMNational Historic Marker Daymariettatimes.com - April 25 at 11:55 AMVolunteers needed for Historic Marker Day project in Uticaromesentinel.com - April 22 at 7:34 PMTop 8 Best Dry Erase Markers in 2024straight.com - April 21 at 3:28 PMTop 8 Best Chalk Markers in 2024straight.com - April 21 at 10:26 AMGold Star Families Memorial Marker dedication Saturdayhavredailynews.com - April 19 at 3:41 PMReggae Rehab Pool Party with Channel 3 at The Markerbocaratonobserver.com - April 19 at 9:31 AMVolunteers needed for National Historic Marker Dayromesentinel.com - April 16 at 11:03 AMJennett Marker Named Human Resources Manager For Chore-Timetimesuniononline.com - April 13 at 7:52 AMHaliwa-Saponi Indian Tribe to be featured on Highway Historical Markerwarrenrecord.com - April 11 at 12:59 PMMarker Therapeutics Inc (MRKR)investing.com - April 10 at 8:50 PMWin an overnight stay with afternoon tea at Anantara The Marker Dublin Hotel.irishtimes.com - April 10 at 3:36 AMMicroRNA Liquid Biopsy Test Shows Potential for Early Pancreatic Cancer Detectionprecisionmedicineonline.com - April 9 at 5:13 PMPutnam Marker Honoring Warner Sisters Restored At Foundry Point Parkmsn.com - April 9 at 5:13 PMSite of former Allentown State Hospital to receive Official State Historical Markerwfmz.com - April 9 at 5:13 PMRobert Edgar Sherrill Memorial Marker Will Be Dedicated April 25chattanoogan.com - April 9 at 12:13 PMCinco de Mayo Margarita Battle at The Marker Key West Harbor Resortbocaratonobserver.com - April 9 at 12:13 PMPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignanciesglobenewswire.com - April 8 at 7:00 AMVolunteers needed April 26 for National Historic Marker Daywestsidenewsny.com - April 7 at 1:24 PMMorrisound Recording Awarded Historical Marker For Contributions To Extreme Metal, Music Industrymetalinjection.net - April 3 at 2:36 PMGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular Diseasesfinance.yahoo.com - April 3 at 2:36 PMMouse Models and Markers for Cerebral Amyloid Angiopathy, ARIAalzforum.org - March 28 at 5:52 PMThe Andy Westcott Band Concert at The Marker Key West Harbor Resortbocaratonobserver.com - March 27 at 9:34 AMMiddle Passage Marker in Port Arthur commemorates ancestors, provides history of local slave tradepanews.com - March 26 at 5:22 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.AptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.CymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.